Areum Medics announced on the 5th that it has completed the construction of a filler factory with a total floor area of approximately 1,300 square meters in Suwon, Gyeonggi Province, and will begin full-scale production of filler products with an annual capacity of 4 million units.
The facility is equipped with a production environment compliant with Good Manufacturing Practice (GMP) standards and is drawing attention as a strategic base for entering the next-generation filler market. It has been designed with a 'Closing System' to minimize contamination, enabling stable production without external exposure. This has significantly enhanced production yield and hygiene safety. Unusually for the medical device sector, the company has adopted a Quality by Design (QbD) development system, allowing for the production of products with optimal physical properties tailored to each indication.
Through its proprietary 'MIRACLE Method' platform technology, Areum Medics has overcome the limitations of first-generation fillers and developed a dual-phasic filler product with high elasticity and high cohesiveness. The method precisely controls cross-linking conditions such as temperature, concentration, and time, delivering superior performance in terms of ease of procedure, wrinkle improvement, and long-lasting effects.
DongKoo Bio & Pharma, the largest shareholder of Areum Medics, is the leading company in dermatology prescriptions in Korea and possesses a nationwide hospital and clinic distribution network, global partnership networks, and overseas corporate infrastructure. With the completion of the factory, comprehensive collaborative synergy between the two companies is anticipated. They are strengthening their presence in the global aesthetic and plastic surgery market through joint R&D, overseas registration strategies, and premium brand launches.
The linkage with local distribution channels established by DongKoo Bio & Pharma in Southeast Asia, Mongolia, Brazil, and other regions is expected to provide substantial momentum for accelerating exports of Areum Medics products.
Areum Medics plans to produce a variety of product lines at this factory, including functional fillers, polymer fillers, and large-capacity fillers. The company intends to pursue both domestic and international regulatory approvals and exports through a system that meets domestic GMP certification and global quality standards. The first hyaluronic acid (HA) filler product aims to complete GMP certification within the third quarter of 2025 and obtain approval from the Ministry of Food and Drug Safety through domestic clinical trials by the end of 2027.
The company will also actively expand exports to Southeast Asian markets with its existing export-oriented HA filler products. Choyongjun, CEO of DongKoo Bio & Pharma, stated, "The completion of the Areum Medics Suwon factory will serve as a stepping stone for global market entry through strategic collaboration with DongKoo Bio & Pharma," adding, "We expect it to become a key production base for the premium filler market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
